{
    "clinical_study": {
        "@rank": "149489", 
        "arm_group": {
            "arm_group_label": "Heart failure, sleep-disordered breathing", 
            "description": "Patients with stable heart failure NYHA \u2265 II, EF \u2264 45% with or without central sleep apnea (apnea-hypopnea index \u2265 15/h) with or without adaptive servoventilation"
        }, 
        "brief_summary": {
            "textblock": "Prospective, follow-up registry of heart failure patients with or without sleep-disordered\n      breathing (SDB). To test the hypothesis that treatment of nocturnal central sleep apnea with\n      Cheyne-Stokes respiration by adaptive servoventilation (ASV) improves symptoms, cardiac\n      performance and event-free survival."
        }, 
        "brief_title": "Effects of Adaptive Servoventilation in Patients With Systolic Heart Failure and Sleep-Disordered Breathing", 
        "completion_date": {
            "#text": "March 2022", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Heart Failure, Congestive", 
            "Sleep Apnea Syndromes", 
            "Adaptive Servoventilation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Apnea", 
                "Heart Failure", 
                "Sleep Apnea Syndromes", 
                "Heart Failure, Systolic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is intended to investigate therapeutic effects of adaptive servoventilation in\n      patients with sleep-disordered breathing and chronic heart failure. These effects include\n      short-/long-term effects on\n\n        -  symptoms and quality of life\n\n        -  physical and cardiac performance (6min walking test, cardiopulmonary exercise testing)\n\n        -  echocardiographic parameters\n\n        -  arrhythmias\n\n        -  NT-proBNP\n\n        -  Respiratory stability (blood gases, rebreathing test, VE/VCO2-slope in cardiopulmonary\n           exercise testing)\n\n        -  Compliance with ASV therapy\n\n        -  Event free survival (death, heart transplantation, assist device implantation)\n\n      All of these data are also obtained in patients who basically meet the inclusion criteria\n      but in whom sleep-disordered breathing was excluded by means of cardiorespiratory polygraphy\n      or polysomnography and in patients with sleep-disordered breathing who do not undergo\n      adaptive servoventilation for various reasons."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Stable heart failure NYHA \u2265 II\n\n          -  EF \u2264 45%\n\n          -  without sleep-disordered breathing (apnea-hypopnea-index <5/h) and those with\n             moderate to severe central sleep apnea (apnea-hypopnea index \u2265 15/h) with or without\n             adaptive servoventilation therapy\n\n        Exclusion Criteria:\n\n          -  Cardiac resynchronization or pacemaker implantation within the last 6 months\n\n          -  Significant COPD with an forced expiratory one-second capacity relative to vital\n             capacity (FEV1/VC)< 70% (GOLD III)\n\n          -  Respiratory insufficiency requiring long-term oxygen therapy\n\n          -  Daytime hypercapnia at rest (pCO2 > 45 mmHg)\n\n          -  Current ventilation therapy\n\n          -  Cardiac surgery, PCI, myocardial infarction, unstable angina, TIA or stroke within 12\n             weeks prior to randomization\n\n          -  Acute myocarditis within 6 months prior to randomization\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients of a university hospital"
            }
        }, 
        "enrollment": {
            "#text": "1500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657188", 
            "org_study_id": "HDZNRW_KA_001_OO"
        }, 
        "intervention": {
            "arm_group_label": "Heart failure, sleep-disordered breathing", 
            "intervention_name": "Cheyne-Stokes respiration by adaptive servoventilation", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart failure, congestive", 
            "Sleep apnea syndromes", 
            "Adaptive servoventilation", 
            "Prognosis", 
            "Cheyne-Stokes respiration"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bad Oeynhausen", 
                    "country": "Germany", 
                    "zip": "32545"
                }, 
                "name": "Department of Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Effects of Adaptive Servoventilation in Patients With Systolic Heart Failure and Sleep-Disordered Breathing", 
        "overall_official": {
            "affiliation": "Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum", 
            "last_name": "Olaf Oldenburg, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This prospective registry includes heart failure patients with or without accompanied sleep-disordered breathing and investigates its influence on symptoms, cardiac function and performance, quality of life and outcome.", 
            "measure": "Influence of adaptive servoventilation on heart failure parameters including event free survival", 
            "safety_issue": "No", 
            "time_frame": "Time frame for event free survival analysis is up to 8 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657188"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ruhr University of Bochum", 
            "investigator_full_name": "Olaf Oldenburg", 
            "investigator_title": "Senior cardiologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Ruhr University of Bochum", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ruhr University of Bochum", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}